Table 2.

Leading non‐peptide therapeutics undergoing trials for SARS‐CoV‐2

Therapeutic name	Biological mechanism	Outcome
Remdesivir	Repurposed RdRP inhibitor for Ebola and Marburg virus	Reduced replication in respiratory system May reduce mortality
Ebastine	Repurposed second generation antihistamine H1 agonist	Inhibits T‐cell activation and migration (specifically TNF‐α and GM‐CSF).
Danoprevir a)	Repurposed chronic Hepatitis C Protease (NS3/4A) inhibitor	Inhibits chymotrypsin‐like proteases (essential in viral replication)
Casirivimab/Imdevimab	Experimental SARS‐CoV‐2 monoclonal antibody	Shorted duration of symptoms Reduced viral load
Bamlanivimab/Etesevimab	Experimental SARS‐CoV‐2 monoclonal antibody	Reduced mortality and hospitalizations Reduced viral load

^a) in conjunction with Ritonavir.